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(PBMCs)were reprogrammedusing heat sensitive non-integrative Sendai viruses containing the reprogramming
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by RT-PCR. Characterization of BSS1-PBMC-iPS4F4 included mutation analysis of GPIX locus, Short Tandem Re-
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associated factors at mRNA and protein level and in vivo differentiation studies. BSS1-PBMC-iPS4F4 will provide
a powerful tool to study BSS.
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Bernard Soulier syndrome (BSS) is an inherited autosomal recessive
rare platelet disorder caused by mutations in the genes coding for the
membrane glycoprotein complex GPIb-IX-V (Berndt and Andrews,
2011). In this study we generated an iPSC line from PBMCs of a BSS pa-
tient containing the mutation p.Trp71Arg in the GPIX gene (PBMCs-
BSS1) (Sánchez-Guiu et al., 2014). This new iPSC line was named
BSS1-PBMC-iPS4F4.
We used CytoTune iPS 2.0 Reprograming System (Life Technologies,
Invitrogen) that contains the vectors used for delivering and expressing
the reprogramming factors Oct3/4, Sox2, Klf4 and c-Myc to reprogram
PBMCs-BSS1 (Takahashi et al., 2007; Yu et al., 2007). Sequencing analy-
sis of the GPIX locus conﬁrmed the presence of c. 259 T N C change in
exon 3 of the GPIX gene corresponding to a homozygous p.W71Rmuta-
tion, identical to PBMCs-BSS1 (Fig. 1A). Additionally, Short Tandem Re-
peat (STR) proﬁling conﬁrmed same genetic identity between both
samples (Table 1). This iPSC line silenced the expression of exogenous
reprogramming transgenes after 8 passages (Fig. 1B) and showed nor-
mal karyotype (46, XX) (Fig. 1C). BSS1-PBMC-iPS4F4 colonies displayed
typical round shape morphology and they were positive for alkaline
phosphatase activity (Fig. 1D).
BSS1-PBMC-iPS4F4 expressed the endogenous pluripotent tran-
scription factors OCT3/4, SOX2, REX1 and NANOG, assessed by RT-PCR
(Fig. 2A) and the protein pluripotent markers SSEA3, SSEA4, Tra1–60,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Characterization of BSS1-PBMC-iPS4F4 cell line. (A) Sequence analysis of c. 259 T N C change in exon 3 of the GPIX gene from control iPSC line (PBMC1-iPS4F1) (left panel), BSS1-
PBMC (middle panel) and BSS1-PBMC-iPS4F4 (right panel). (B) Silencing of exogenous reprogramming factors and SeV vector conﬁrmed by RT-PCR. H9 cell line was used as a negative
control and BSS1-PBMC-iPS4F4 at passage 2was used as a positive control. (C) GTG-banding shows a normal karyotype inBSS1-PBMC-iPS4F4 cell line. (D)Alkaline phosphatase enzymatic
activity staining.
693L. Lopez-Onieva et al. / Stem Cell Research 16 (2016) 692–695Tra1–81 and Oct3/4, evaluated by ﬂow cytometry analysis (Fig. 2B). To
demonstrate the capacity of BSS1-PBMC-iPS4F4 to differentiate into the
three germ layers in vivo, teratoma formation assayswere accomplishedTable 1
Short Tandem Repeat (STR) proﬁling of the original patient cells (BSS1-PBMC) and the
iPSC patient-derived cells (BSS1-PBMC-iPS4F4).
Allele Proﬁle
BSS1-PBMC BSS1-PBMC-iPS4F4
Amelogenin X X
CSF1PO 10 10
D3S1358 14, 15 14, 15
D5S818 11, 12 11, 12
D7S820 9, 10 9, 10
D8S1179 11, 16 11, 16
D13S317 8, 11 8, 11
D16S539 1, 12 1, 12
D18S51 13, 14 13, 14
D19S433 13, 14 13, 14
D21S11 30 30
FGA 19, 23 19, 23
TH01 8, 9.3 8, 9.3
TPOX 8, 9 8, 9
vWA 17, 18 17, 18(6). As shown in Fig. 2C, teratomas derived from this line showed ex-
pression of representative markers of ectoderm (β3-Tubulin), meso-
derm (Vimentin) and endoderm (Cytokeratin CK AE1–AE) (Fig. 2C).Materials and methods
Generation of BSS1-PBMC-iPS4 line from PBMCs-BSS1
Peripheral blood sample was obtained from a womanwith BSS after
informed consent according with the Andalusian Ethics Review Board
for Cellular Reprogramming requirements andwith Spanish and EU leg-
islation. BSS1-PBMCs were isolated by centrifugation using Ficoll
Paque™ PLUS (GE Healthcare). Isolated BSS1-PBMCs were cultured in
StemSpan™ SFEM (StemCell Technologies) supplemented with
100 ng/ml hSCF, 100 ng/ml hFLT3L, 20 ng/ml hTPO, 10 ng/ml G-CSF
and 2 ng/ml hIL3 (Peprotech) for four days. Then, mononuclear cells
were transferred to a 12-well ﬁbronectin coated plate (BD BioCoat™)
and Sendai virus (SeV) (CytoTune®-iPS 2.0 Reprogramming kit, Life
Technologies, Invitrogen) were added at a multiplicity of infection of
three (MOI:3) in the presence of 8 μg/ml Polybrene (Sigma-Aldrich)
and 10 μM Y-27,632 (Sigma-Aldrich). Three days after transduction,
cells were co-cultured in StemSpan™ SFEM (StemCell Technologies)
Fig. 2. Pluripotency markers and in vivo differentiation capacity of BSS1-PBMC-iPS4F4 line. (A) Endogenous pluripotencymarkers OCT4, SOX2, REX1 y NANOGwere conﬁrmed by RT-PCR.
(B) Expression of pluripotency-associatedmarkers SSEA3, SSEA4, TRA1–81, TRA 1–60 and OCT3/4 at protein level by FACS analysis. The inset shows the staining using the corresponding
irrelevant isotype-matched antibody. (C) In vivo differentiation test by teratoma formation assay. Histological sections from13week-teratomas developed in the dorsalﬂanks of SCIDmice
following injection with BSS1-PBMC-iPS4F4. Hematoxylin and eosin (H&E) staining reveals characteristic tissues from the three germ layers (left panel); immunohistochemistry analysis
showed differentiation to mesoderm (Vimentin), endoderm (CK AE1–AE3) and ectoderm (β3-Tubulin).
Table 2
Primers sets used for DNA sequencing and RT-PCR.
Gene Primer sequence Product size
GPIX-P4 Forward: GATGGGGTCTCTGCTAAGGG 1070 bp
Reverse: AGCCCCAACTGATGTCTGGT
β-ACTIN Forward: CTGGAACGGTGAAGGTGACA 165 bp
Reverse: AAGGGACTTCCTGTAACAATGCA
OCT4 Forward: AGTGAGAGGCAACCTGGAGA 110 bp
Reverse: ACACTCGGACCACATCCTTC
SOX2 Forward: TCAGGAGTTGTCAAGGCAGAGAAG 80 bp
Reverse: CTCAGTCCTAGTCTTAAAGAGGCAGC
REX1 Forward: CAGATCCTAAACAGCTCGCAGAAT 306 bp
Reverse: GCGTACGCAAATTAAAGTCCAGA
NANOG Forward: TGCAGTTCCAGCCAAATTCTC 96 bp
Reverse: CCTAGTGGTCTGCTGTATTACATTAAGG
SeV Forward: GGATCACTAGGTGATATCGAGC 181 bp
Reverse:ACCAGACAAGAGTTTAAGAGATATGTATC
KOS Forward: ATGCACCGCTACGACGTGAGCGC 528 bp
Reverse: ACCTTGACAATCCTGATGTGG
KLF4 Forward: TTCCTGCATGCCAGAGGAGCCC 410 bp
Reverse: AATGTATCGAAGGTGCTCAA
c-MYC Forward: TAACTGACTAGCAGGCTTGTCG 532 bp
Reverse: TCCACATACAGTCCTGGATGATGATG
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stem cells (hMSCs, Inbiobank). Six days after transduction cells were
adapted to pluripotent stem cell (PSC) medium consisting in KO-
DMEM (Life Technologies) supplemented with 10% knockout serum re-
placement (Life Technologies), 8 ng/ml bFGF2 (Milteny Biotec), 10 μM
Y-27632 (Sigma-Aldrich), 1 mM glutamine, 1% MEM non-essential
amino acids and 0.1 mM 2-mercaptoethanol (all from Life Technolo-
gies). From day seven onwards cells were cultured in PSC medium. On
day 12 after transduction emerging iPSC colonies were picked individu-
ally and expanded for characterization. Fromday 3 to day 21 after trans-
duction, cells were cultured in a dedicated 37 °C chamber with 5% CO2
and 5% O2.
Mutational analysis
Genomic DNA was isolated from PBMC of BSS1 patient (BSS1-
PBMCs), BSS1-PBMC-iPS4 line and a healthy control iPSC line (PBMC1-
iPS4F1 line (Montes et al., 2015)) using the DNAextraction kit (Qiagen).
PCR ampliﬁcation with a set of primers ﬂanking the mutation site (Set
GPIX-4P, see Table 2) was performed in all three samples following
the manufacturer's instructions. PCR products were sequenced using
primer GPIX-4P Forward by Sanger sequencing on an ABI 3130 Genetic
Analyzer.
Short tandem repeat (STR) proﬁling
Toverify the origin of thenew iPSC line generated, DNA fromperiph-
eral blood mononuclear cells from the BSS1 patient (BSS1-PBMC) and
BSS1-PBMC-iPS4F4were puriﬁed. AmpFlSTR® Idenﬁﬁler® PCR Ampliﬁ-
cation kit (Applied Biosystems, Life Technologies) was used to deter-
mine the genetic signature of both samples based on the multiplex
analysis of 15 loci and the Amelogenin gender-determining marker.PCR products were run in the ABI3130 genetic analyzer (Applied
Biosystems, Life Technologies) and analyzed using the GeneMapper®
ID Software (Applied Biosystems, Life Technologies) following the
manufacturer's recommendations. As shown in Table 1, BSS1-PBMC-
iPS4F4 conserves identical STR proﬁle than the original BSS1-PBMC.
Semiquantitative RT-PCR
Total RNA from undifferentiated BSS1-PBMC-iPS4 andH9 (Thomson
et al., 1998) lines was isolated using the High pure RNA isolation kit
695L. Lopez-Onieva et al. / Stem Cell Research 16 (2016) 692–695(Roche) and cDNAwas generated using the Transcription First Strand c-
DNA synthesis kit (Roche) according to themanufacturer's instructions.
PCR was performed using Taq DNA Polimerase kit (Invitrogen, Life
Technologies). PCR products were electrophoresed in an agarose gel.
The primers used are listed in Table 2. KLF4, SeV, c-MYC and KOS primer
sets were used to determine the presence of exogenous reprogram
factors. Oct3/4, SOX2, NANOG and REX1 and β-ACTIN primer sets were
used to conﬁrm the expression of pluripotent markers (Ramos-Mejía
et al., 2012).
Karyotyping
Chromosomal analysis was performed by GTG-banding analysis at
the Andalusian Public Health System Biobank, Spain, following the In-
ternational System Cytogenetics Nomenclature recommendations
(Simons et al., 2013; Catalina et al., 2007).
Alkaline phosphatase
After ﬁve days in culture, BSS1-PBMC-iPS4 colonieswere assayed for
phosphatase alkaline enzymatic activity using a commercial detection
kit (Merck-Millipore) according to the manufacturer's instructions.
Flow cytometry analysis
BSS1-PBMC-iPS4 colonies were dissociated using Tryple Express
(Life Technologies) and the cell suspension was stained with SSEA3
(PE, BioScience), SSEA4 (Alexa Fluor® 647, BD Pharmingen), Tra1-60
(PE, BioScience), Tra1-81 (Alexa Fluor® 647, BD Pharmingen) surface
antibodies for 30 min. Intracellular staining for Oct3/4 was performed
by sequential incubations with ﬁxation and permeabilization solutions
(A and B Fix & Perm Solutions, Invitrogen). Then cells were incubated
ﬁrst with Oct3/4 (BD BioScience) primary antibody, and subsequently
with FITC-conjugated secondary antibody (BD BioScience). After wash-
ing, cells were stained with 7-aminoactinomycin D (7-AAD) (BD Biosci-
ence) for 5 min at RT. An irrelevant isotype-match antibody was always
used as a negative control. Live cells were identiﬁed by 7-AAD exclusion
and were analyzed using a FACS verse (BD Bioscience).
In vivo teratoma formation
Feeder free BSS1-PBMC-iPS4 colonies were dissociatedwith collage-
nase IV (Gibco) and resuspended in PBS. 2− 5 × 106 cells per mouse
were subcutaneously implanted into the dorsal ﬂanks of SCID mice
(NOD/LtSz-scid interleukin-2Rγ−/− mice, The Jackson Laboratory).
Teratoma growth was monitored weekly and mice were sacriﬁced at13 weeks post implantation. Teratomas were collected, ﬁxed in
formaldhyde, embedded in parafﬁn, sectioned and stained with hema-
toxylin and eosin ((H&E) for histological analysis. Immunocytochemistry
analysis for β3-Tubulin (ectoderm), Vimentin (mesoderm) and CKAE1-
EA3 (endoderm) was performed on sectioned slides (Gutierrez-Aranda
et al., 2010). The Animal Care Ethics Committee of the University of
Granada approved all animal protocols.
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